BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Dostarlimab: trial readouts and FDA decisions
4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 6 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: GlaxoSmithKline, Tesaro, Inc., iOnctura. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-23 est. | P2 | GlaxoSmithKline | NCT06567782 A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient | Neoplasms, Colon | recruiting | 120 |
| 2026-11-26 est. | P3 | Tesaro, Inc. | NCT03981796 A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endome | Neoplasms | active not recruiting | 785 |
| 2026-12-14 est. | P2 | GlaxoSmithKline | NCT06317311 A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | Carcinoma | active not recruiting | 41 |
| 2027-01 est. | P1/P2 | iOnctura | NCT06879717 A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Advanced Non Squamous NSCLC | active not recruiting | 45 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-02 est. | P2 | GlaxoSmithKline | NCT05723562 A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer | Neoplasms, Rectal | active not recruiting | 154 |
| 2026-10-26 | P2 | GlaxoSmithKline | NCT05565378 A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | Lung Cancer, Non-Small Cell | active not recruiting | 351 |
| 2026-10-13 est. | P1/P2 | GlaxoSmithKline | NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrin | active not recruiting | 83 |
| 2026-09-10 | P2 | GlaxoSmithKline | NCT06062420 A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of | Neoplasms, Head and Neck | active not recruiting | 316 |
| 2026-07-13 | P1/P2 | GlaxoSmithKline | NCT06405230 Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positro | Lung Cancer, Non-Small Cell | terminated | 2 |
| 2026-06-30 | P3 | GlaxoSmithKline | NCT06472076 A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) Hig | Lung Cancer, Non-Small Cell | active not recruiting | 88 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.